Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it ...

In an era where most carmakers are clutching their pearls over rising costs, falling margins, and the existential dread of ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or ...

It’s an Aston-Martin silencer. A Lucid humbler ... of course, they own the patent. Private Office commissions command a 25% premium over even standard Bespoke orders. But they come with a ...

VitaRNA recently filed its second patent for ARTAN-102, a tRNA suppressor that offers a potential breakthrough for mutation-driven diseases. Vita-FAST raised $620,000 to support Newcastle ...

amber suppressor. In eukaryotic cells, logic gates can be built by rearranging protein-protein interaction domains. Wendell Lim built a variety of logic blocks using modular domains (such as PDZ ...

Patent Bots proofread an entire year of issued patents to determine the top patent firms. Somerville, MA: Patent Bots, creator of AI-enabled software for patent attorneys, is pleased to announce ...

While Washington's endless drama dominates headlines, the Trump administration has been rewiring the foundations of American intellectual property (IP) policy. The administration's pro-patent ...

A federal jury in San Francisco has handed down a unanimous verdict clearing Motive Technologies Inc. of allegations it copied patents owned by technology developer Omnitracs. The jury’s April ...

One of San Antonio’s biggest employers is no stranger to patent lawsuits. USAA has filed several in Texas courts over competitors’ use of mobile check cashing software the San Antonio-founded ...